IT Pro is supported by its audience. When you purchase through links on our site, we may earn an affiliate commission. Learn more

Sensome’s AI-powered stroke guidewire begins human trials in Australia

The trial adds to Sensome’s multicenter CLOT OUT study

Sensome has begun human trials for its artificial intelligence (AI)-powered stroke guidewire at the Gold Coast University Hospital (GCUH).

The trial will evaluate the safety and efficacy of the Sensome’s Clotild Smart Guidewire system in acute ischemic stroke patients. 

CLOT OUT is Sesome’s first-in-human, multicenter trial earmarked for leading stroke centers across Australia, Belgium, and France. The GCUH trial adds to this initiative. 

Replacing invasive medical procedures, Sensome’s Clotild Smart Guidewire system pairs impedance-based tissue sensors with machine learning algorithms to provide physicians with valuable insights into the clot.

The AI-powered system recently gained FDA approval to aid in treating or diagnosing life-threatening and irreversibly debilitating diseases and conditions.

“Endovascular thrombectomy is no longer just about removing the clot. To get the best result for your patient, you need to get the clot out with complete revascularization the first time,” explains Dr. Hal Rice, director of interventional neuroradiology at GCUH.

Rice added, “The Clotild guidewire is the first device that promises to provide live real-time information during the intervention that can help increase our chances to choose the right interventional approach from the get-go.”

Related Resource

Pharma transactions during the COVID-19 pandemic

How resilient were they?

Whitepaper front coverFree download

According to reports, Sensome aims to enroll up to 100 patients in its CLOT OUT study. Data from preliminary cases will be presented at this year's LINNC conference in Paris and at SLICE Worldwide, an online interactive stroke event.

“Evidence has been mounting over the past few years that factors like the biological clot composition should be considered when choosing the fastest method to remove a clot. The CLOT OUT trial aims to demonstrate that using Clotild in humans is safe and can detect clot composition,” stated Dr. Andrew Cheung, co-coordinating investigator of the study at Liverpool Hospital.

Featured Resources

Accelerating healthcare transformation through patient-centred medtech solutions

Seize the digital transformation opportunities to streamline patient care and optimise patient outcomes

Free Download

Big payoffs from big bets in AI-powered automation

Automation disruptors realise 1.5 x higher revenue growth

Free Download

Hyperscaler cloud service providers top ten

Why it's important for companies to consider hyperscaler cloud service providers, and why they matter

Free Download

Strategic app modernisation drives digital transformation

Address business needs both now and in the future

Free Download

Recommended

The future of food and beverage manufacturing
Whitepaper

The future of food and beverage manufacturing

21 Nov 2022
Discrete manufacturing in a changing world
Whitepaper

Discrete manufacturing in a changing world

21 Nov 2022
Big payoffs from big bets in AI-powered automation
Whitepaper

Big payoffs from big bets in AI-powered automation

26 Oct 2022
The Total Economic Impact™ of IBM robotic process automation
automation

The Total Economic Impact™ of IBM robotic process automation

25 Oct 2022

Most Popular

Empowering employees to truly work anywhere
Sponsored

Empowering employees to truly work anywhere

22 Nov 2022
Larger monitors aren't all they're cracked up to be
monitors

Larger monitors aren't all they're cracked up to be

3 Dec 2022
Defra's legacy software problem 'threatens' UK gov cyber security until 2030
Business strategy

Defra's legacy software problem 'threatens' UK gov cyber security until 2030

6 Dec 2022